Starton Holdings
(Incorporated in Delaware) We are a Phase 2 biopharmaceutical company developing continuous delivery technology for existing FDA-approved cancer treatments. Our lead program, STAR-LLD, targets multiple myeloma and chronic lymphocytic leukemia. We are investigating the potential of combining STAR-LLD with CAR-T therapies and extending our work to include other types of cancer such as B-cell lymphomas […]
April 8, 2026 Read More